[Acute effect of prostigmin on lung function and breathing of patients with myasthenia gravis at rest and following ergometric exercise].
The acute effects of a single intravenous Prostigmin injection (0.5 mg) on lung function and gas exchange during rest and bicycle ergometry were measured in 26 patients with myasthenia gravis. The mean age of the patients was 44.6 +/- 17.6 years and the mean duration of myasthenia gravis 5.4 +/- 6.3 years. Lung function parameters obtained from 15 patients showed a normal total lung capacity with an increase in functional residual capacity and residual volume, while vital capacity was diminished. While the application of Prostigmin showed no acute effects on these lung volumes, there was a significant increase in airway resistance, even into the pathologic range. Data obtained during spiro-ergometry concerning gas exchange, circulation and muscle metabolism correspond to those expected from healthy individuals; application of Prostigmin did only influence the heart rate, which can be explained by parasympathomimetic activity. We conclude that dyspnoea in patients with myasthenia gravis need not necessarily be a symptom of the illness itself but can also be caused by therapy; in the latter case bronchodilatators are required.
Haber
P
P
II. Medizinische Universitäts-Klinik, Wien, Osterreich.
Harmuth
P
P
Wolf
C
C
Mayr
N
N
Zeithofer
J
J
D000328:Adult; D000368:Aged; D000403:Airway Resistance / Q000187:drug effects; D005080:Exercise Test; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000503:physiopathology*; D009388:Neostigmine; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D012129:Respiratory Function Tests
D009388:Neostigmine
Akute Effekte von Prostigmin auf Lungenfunktion und Atmung von Patienten mit Myasthenia gravis in Ruhe und bei dosierter Ergometerbelastung.